Faeth Therapeutics, Inc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): diluted EPS of -$0.79. It usually reports 34–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 15, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on how many days after a quarter ends the company has reported recently. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
-20
-346.4%
|
-0.79
+78.2%
|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-16
-224.3%
|
-2.84
+27.4%
|
|
May 15, 2026
45 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-170
-2380.1%
|
-131.45
-2311.9%
|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-5
+37.0%
|
-3.62
+37.3%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-5
+30.9%
|
-3.91
+31.3%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-7
+14.1%
|
-5.45
-1603.1%
|
|
Nov 14, 2024
45 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
|
Aug 6, 2024
37 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1829802
- Former names
- Sensei Biotherapeutics, Inc. (until Jun 16, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.